Alex Zhavoronkov, PhD, is the founder, CEO,and CBO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative AI and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative AI and reinforcement learning for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. Under his leadership, Insilico raised over $530 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 8 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated more than 22 preclinical candidates, 10 of which reached clinical stage, and one program with a novel target and novel molecule completed Phase IIa in idiopathic pulmonary fibrosis with favorable safety, tolerability, and encouraging dose-dependent efficacy.

Since 2012, Dr. Zhavoronkov has published over 310 peer-reviewed research papers, with over 30 papers in the field of generative adversarial networks, generative reinforcement learning, and multi-modal transformers, and three books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the annual Aging Research and Drug Discovery Meeting. Dr. Zhavoronkov is the adjunct professor of AI at the Buck Institute for Research on Aging.

‍